Your browser doesn't support javascript.
loading
TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao, Peiqi; Li, Lanfang; Zhou, Shiyong; Qiu, Lihua; Qian, Zhengzi; Liu, Xianming; Cao, Xuchen; Zhang, Huilai.
Afiliación
  • Zhao P; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianji
  • Li L; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianji
  • Zhou S; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianji
  • Qiu L; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianji
  • Qian Z; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianji
  • Liu X; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianji
  • Cao X; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin Medical University, Tianjin 300060, China. Electron
  • Zhang H; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianji
Mater Sci Eng C Mater Biol Appl ; 84: 108-117, 2018 Mar 01.
Article en En | MEDLINE | ID: mdl-29519418
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Portadores de Fármacos / Dióxido de Silicio / Nanopartículas / Antineoplásicos Límite: Animals / Female / Humans Idioma: En Revista: Mater Sci Eng C Mater Biol Appl Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Portadores de Fármacos / Dióxido de Silicio / Nanopartículas / Antineoplásicos Límite: Animals / Female / Humans Idioma: En Revista: Mater Sci Eng C Mater Biol Appl Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos